Our next journal club, held jointly with the DIA, features two papers on the topic of Statistical Considerations for Innovative Designs in Clinical Trials. Please join us to hear Jason Yuan and Xiangmin Zhang present their recent work:
In preparation and prior to the day of the webinar, please follow the link above to obtain your personal dial in details and register with the webinar software. After registering via this link, you will receive a confirmation email containing information about joining the webinar, including details on how to dial-in via the telephone. Please allow enough time before joining to download the correct software.
Papers available to view prior to the meeting on http://www.psiweb.org/events/journal-club and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website. The meetings are open to PSI and non-PSI members.
We encourage you to read these papers in advance so you get the most from this event. For further info/feedback, or to submit a question to the authors in advance of the meeting please contact email@example.com
Joint PSI, EFSPI & ASA BIOP Webinar: Estimands
PSI, the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) and the Biopharmaceutical Section of the American Statistical Association (ASA) are jointly organising a webinar on Estimands in Practice. Speakers from regulatory authorities (FDA and EMA) and industry will present on their experience on this topic to date.
Discover your potential by working as a Covance Senior Principal / Principal Biostatistician. You'll enjoy a varied role working for different sponsors across several therapeutic areas, leading projects and mentoring junior members of the department.
Biometrics at AstraZeneca provides the data that influences decisions on how we roll back the frontiers of science to bring life-changing medicines to the world. We are at the heart of design, analytics and interpretation of AstraZeneca’s portfolio.